CTRI/2020/10/028440尚未招募2 期
A phase 2, randomized, double-blind, double-dummy, Placebo-controlled, dose-ranging, dose-finding, parallelgroup study to assess efficacy and safety of PF-06865571 (DGAT2i) alone and when coadministered with PF-05221304 (ACCi) in adult participants with biopsy-confirmed nonalcoholic Steatohepatitis and fibrosis stage 2 or 3
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- Pfizer Inc
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •(1)Biopsy proven NASH with either F2 or F3 fibrosis, per NASH CRN definition
- •(2)BMI more than or equal to 22.5kg/m2
排除标准
- •(1)Evidence of other causes of liver disease such as Alcoholic steatohepatitis, (de)compensated cirrhosis, active viral hepatitis
- •(2)Any condition possibly affecting drug absorption -Unstable concomitant medical conditions, based on medical history or screening laboratory results including-
- •(3)unstable liver function tests, recent cardiovascular event(s) significant malignancies,
研究者
相似试验
已完成
不适用
Phase II multi-centre study to evaluate efficacy, safety, and immunogenicity of GMZ2 candidate malaria vaccine in children aged 12 to 60 monthsPaediatricsMalariaPACTR2010060002033537Statens Serum Intitute1,840
进行中（未招募）
2 期
Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)onalcoholic SteatohepatitisJPRN-jRCT2071210112Kamiya Makoto440
进行中（未招募）
1 期
A study to assess the safety and efficacy of Semaglutide and the fixed dose combination of Cilofexor and Firsocostat, alone and in combination, in subjects with Chirrhosis due to Nonalcoholic Steatohepatitis (NASH)onalcoholic Steatohepatitis (NASH)MedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-001445-12-ESGilead Sciences, Inc.440
进行中（未招募）
不适用
A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter,Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2Dose Regimens of TP-434 Compared with Ertapenem in Adult Community-Acquired Complicated Intra-abdominal InfectionsCommunity-acquired complicated intra-abdominal infectionMedDRA version: 12.1Level: LLTClassification code 10056570Term: Intra-abdominal infectionEUCTR2010-022548-19-BGTetraphase Pharmaceuticals, Inc.200
招募中
2 期
A clinical study to estimate the safety, tolerability and efficacy of two medications for treatment of complicated intra abdominal infections in adults.CTRI/2011/10/002076Tetraphase Pharmaceuticals Inc150